Bioxytran, Inc. is a biopharmaceutical company whose mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.
The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The Company’s lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat Ischemic brain strokes, also known as Cardiac Cerebrovascular Accidents (CVA). In addition, our drug candidate, BXT-252, will be tested as a regenerative agent in a variety of wound healing applications.
Bioxytran, Inc. is working to develop new molecules that address unmet medical needs. Bioxytran, Inc.’s drug candidates have a large market potential as anti-necrotic drugs for multiple disease indications that result from hypoxia.